In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study.
❓ Unknown
Immunotherapy Combination Significantly Improves Survival for Small Cell Lung Cancer Patients
Just now
October 26, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A clinical trial demonstrated that the combination of tarlatamab and durvalumab significantly improves survival rates for patients with extensive-stage small cell lung cancer. This advancement in cancer treatment could have implications for healthcare advancements in Iran, particularly in oncology.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Three Executed in Isfahan: A Woman for Murder and Two Men for Drug Offenses
13 min ago •
Biomarkers for Risk of Cytokine Release Syndrome After CAR T-Cell Therapy Identified
13 min ago •
How Shoes Influence Bone Structure and Human Evolution
14 min ago •
The Importance of Urban Green Spaces for Biodiversity Conservation
22 min ago •